FBXO11 and myelodysplastic syndrome: Given our observation that FBXO11-deficient MDS-L cells gained the ability to grow in the absence of cytokines, we were interested in testing whether reduced FBXO11 expression is observed in secondary AML, which would be consistent with FBXO11 downregulation being one pathway for leukemic transformation.